Exollence Biotechnology

Exollence Biotechnology is a South Korean private biotech company developing exosome-based therapeutics and delivery technologies. Its core SWEET platform, short for Shock Wave Exosome Engineering Technology, is designed to load payloads such as siRNA, mRNA, and proteins into exosomes derived from multiple sources for therapeutic delivery. The company appears focused on oncology and inflammatory disease, with preclinical programs that include KRAS-targeted exosome therapeutics and an NLRP3-directed program for inflammatory bowel disease. Exollence also describes broader capabilities spanning exosome drug delivery, vaccines, and target-loaded extracellular vesicle products. The company is active in Seoul Biohub and open-innovation activities and remains a private, early-stage platform biotech.